# A Study to Assess the Long-term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder

> **NCT00635076** · PHASE4 · TERMINATED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 3 (actual)

## Conditions studied

- Panic Disorder

## Interventions

- **OTHER:** placebo
- **DRUG:** alprazolam XR

## Key facts

- **NCT ID:** NCT00635076
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-07
- **Primary completion:** —
- **Final completion:** 2004-09
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Please see Detailed Description for the termination reason.
- **Last updated:** 2021-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00635076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00635076, "A Study to Assess the Long-term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00635076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*